APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine Imaging Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nuclear Medicine Imaging Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

25 December 2025193 pages

Choose your research edition.

Industry ResearchNuclear Medicine Imaging Agents Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Imaging Agents Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Imaging Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Imaging Agents Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Imaging Agents Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Nuclear Medicine Imaging Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nuclear Medicine Imaging Agents include Jubilant Pharma Limited, Foshan Rui Diao Pharmaceutical, Yantai Dongcheng, Navidea, Mallinckrodt, Lantheus, Guerbet, GE HealthCare and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nuclear Medicine Imaging Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Medicine Imaging Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Medicine Imaging Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nuclear Medicine Imaging Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Nuclear Medicine Imaging Agents Segment by Company

Jubilant Pharma Limited

Foshan Rui Diao Pharmaceutical

Yantai Dongcheng

Navidea

Mallinckrodt

Lantheus

Guerbet

GE HealthCare

Eli Lilly and Company

Cardinal Health

Bracco Diagnostic

Blue Earth Diagnostics

Bayer AG

Abx Advanced Biochemical

Nuclear Medicine Imaging Agents Segment by Type

Nitrogen 13 Labeling

Technetium 99 Labeling

Fluorine 18 Labeling

Carbon 11 Labeling

Oxygen 15 Labeling

Others

Nuclear Medicine Imaging Agents Segment by Application

Clinical Stage

Early Diagnosis

Treatment Evaluation

Nuclear Medicine Imaging Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Imaging Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Imaging Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Imaging Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nuclear Medicine Imaging Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nuclear Medicine Imaging Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nuclear Medicine Imaging Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nuclear Medicine Imaging Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nuclear Medicine Imaging Agents Industry Trends Table 2. Nuclear Medicine Imaging Agents Industry Drivers Table 3. Nuclear Medicine Imaging Agents Industry Opportunities and Challenges Table 4. Nuclear Medicine Imaging Agents Industry Restraints Table 5. Global Nuclear Medicine Imaging Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nuclear Medicine Imaging Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nuclear Medicine Imaging Agents Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Nuclear Medicine Imaging Agents Sales Market Share by Manufacturers Table 9. Global Nuclear Medicine Imaging Agents Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Nuclear Medicine Imaging Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nuclear Medicine Imaging Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nuclear Medicine Imaging Agents Manufacturers, Product Type & Application Table 13. Global Nuclear Medicine Imaging Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nuclear Medicine Imaging Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Nitrogen 13 Labeling Table 17. Major Manufacturers of Technetium 99 Labeling Table 18. Major Manufacturers of Fluorine 18 Labeling Table 19. Major Manufacturers of Carbon 11 Labeling Table 20. Major Manufacturers of Oxygen 15 Labeling Table 21. Major Manufacturers of Others Table 22. Global Nuclear Medicine Imaging Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Nuclear Medicine Imaging Agents Sales by Type (2021-2026) & (K Units) Table 24. Global Nuclear Medicine Imaging Agents Sales by Type (2027-2032) & (K Units) Table 25. Global Nuclear Medicine Imaging Agents Sales Market Share by Type (2021-2026) Table 26. Global Nuclear Medicine Imaging Agents Sales Market Share by Type (2027-2032) Table 27. Global Nuclear Medicine Imaging Agents Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Nuclear Medicine Imaging Agents Revenue by Type (2021-2026) & (K Units) Table 29. Global Nuclear Medicine Imaging Agents Revenue by Type (2027-2032) & (K Units) Table 30. Global Nuclear Medicine Imaging Agents Revenue Market Share by Type (2021-2026) Table 31. Global Nuclear Medicine Imaging Agents Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinical Stage Table 33. Major Manufacturers of Early Diagnosis Table 34. Major Manufacturers of Treatment Evaluation Table 35. Global Nuclear Medicine Imaging Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Nuclear Medicine Imaging Agents Sales by Application (2021-2026) & (K Units) Table 37. Global Nuclear Medicine Imaging Agents Sales by Application (2027-2032) & (K Units) Table 38. Global Nuclear Medicine Imaging Agents Sales Market Share by Application (2021-2026) Table 39. Global Nuclear Medicine Imaging Agents Sales Market Share by Application (2027-2032) Table 40. Global Nuclear Medicine Imaging Agents Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Nuclear Medicine Imaging Agents Revenue by Application (2021-2026) & (K Units) Table 42. Global Nuclear Medicine Imaging Agents Revenue by Application (2027-2032) & (K Units) Table 43. Global Nuclear Medicine Imaging Agents Revenue Market Share by Application (2021-2026) Table 44. Global Nuclear Medicine Imaging Agents Revenue Market Share by Application (2027-2032) Table 45. Global Nuclear Medicine Imaging Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Nuclear Medicine Imaging Agents Sales by Region (2021-2026) & (K Units) Table 47. Global Nuclear Medicine Imaging Agents Sales Market Share by Region (2021-2026) Table 48. Global Nuclear Medicine Imaging Agents Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Nuclear Medicine Imaging Agents Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Nuclear Medicine Imaging Agents Sales by Country (2021-2026) & (K Units) Table 52. North America Nuclear Medicine Imaging Agents Sales by Country (2027-2032) & (K Units) Table 53. Europe Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Nuclear Medicine Imaging Agents Sales by Country (2021-2026) & (K Units) Table 55. Europe Nuclear Medicine Imaging Agents Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Nuclear Medicine Imaging Agents Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Nuclear Medicine Imaging Agents Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales by Country (2027-2032) & (K Units) Table 62. Global Nuclear Medicine Imaging Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Nuclear Medicine Imaging Agents Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Nuclear Medicine Imaging Agents Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Nuclear Medicine Imaging Agents Revenue Market Share by Region (2021-2026) Table 66. Global Nuclear Medicine Imaging Agents Revenue Market Share by Region (2027-2032) Table 67. Jubilant Pharma Limited Company Information Table 68. Jubilant Pharma Limited Business Overview Table 69. Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio Table 71. Jubilant Pharma Limited Recent Development Table 72. Foshan Rui Diao Pharmaceutical Company Information Table 73. Foshan Rui Diao Pharmaceutical Business Overview Table 74. Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio Table 76. Foshan Rui Diao Pharmaceutical Recent Development Table 77. Yantai Dongcheng Company Information Table 78. Yantai Dongcheng Business Overview Table 79. Yantai Dongcheng Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio Table 81. Yantai Dongcheng Recent Development Table 82. Navidea Company Information Table 83. Navidea Business Overview Table 84. Navidea Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Navidea Nuclear Medicine Imaging Agents Product Portfolio Table 86. Navidea Recent Development Table 87. Mallinckrodt Company Information Table 88. Mallinckrodt Business Overview Table 89. Mallinckrodt Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio Table 91. Mallinckrodt Recent Development Table 92. Lantheus Company Information Table 93. Lantheus Business Overview Table 94. Lantheus Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Lantheus Nuclear Medicine Imaging Agents Product Portfolio Table 96. Lantheus Recent Development Table 97. Guerbet Company Information Table 98. Guerbet Business Overview Table 99. Guerbet Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Guerbet Nuclear Medicine Imaging Agents Product Portfolio Table 101. Guerbet Recent Development Table 102. GE HealthCare Company Information Table 103. GE HealthCare Business Overview Table 104. GE HealthCare Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio Table 106. GE HealthCare Recent Development Table 107. Eli Lilly and Company Company Information Table 108. Eli Lilly and Company Business Overview Table 109. Eli Lilly and Company Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio Table 111. Eli Lilly and Company Recent Development Table 112. Cardinal Health Company Information Table 113. Cardinal Health Business Overview Table 114. Cardinal Health Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio Table 116. Cardinal Health Recent Development Table 117. Bracco Diagnostic Company Information Table 118. Bracco Diagnostic Business Overview Table 119. Bracco Diagnostic Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio Table 121. Bracco Diagnostic Recent Development Table 122. Blue Earth Diagnostics Company Information Table 123. Blue Earth Diagnostics Business Overview Table 124. Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio Table 126. Blue Earth Diagnostics Recent Development Table 127. Bayer AG Company Information Table 128. Bayer AG Business Overview Table 129. Bayer AG Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Bayer AG Nuclear Medicine Imaging Agents Product Portfolio Table 131. Bayer AG Recent Development Table 132. Abx Advanced Biochemical Company Information Table 133. Abx Advanced Biochemical Business Overview Table 134. Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio Table 136. Abx Advanced Biochemical Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Nuclear Medicine Imaging Agents Distributors List Table 140. Nuclear Medicine Imaging Agents Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Nuclear Medicine Imaging Agents Product Image Figure 2. Global Nuclear Medicine Imaging Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Imaging Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Nuclear Medicine Imaging Agents Sales (2021-2032) & (K Units) Figure 5. Global Nuclear Medicine Imaging Agents Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nuclear Medicine Imaging Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Nitrogen 13 Labeling Image Figure 9. Technetium 99 Labeling Image Figure 10. Fluorine 18 Labeling Image Figure 11. Carbon 11 Labeling Image Figure 12. Oxygen 15 Labeling Image Figure 13. Others Image Figure 14. Global Nuclear Medicine Imaging Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Nuclear Medicine Imaging Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Medicine Imaging Agents Sales Market Share by Type (2021-2032) Figure 17. Global Nuclear Medicine Imaging Agents Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Nuclear Medicine Imaging Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Nuclear Medicine Imaging Agents Revenue Market Share by Type (2021-2032) Figure 20. Clinical Stage Image Figure 21. Early Diagnosis Image Figure 22. Treatment Evaluation Image Figure 23. Global Nuclear Medicine Imaging Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Nuclear Medicine Imaging Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Nuclear Medicine Imaging Agents Sales Market Share by Application (2021-2032) Figure 26. Global Nuclear Medicine Imaging Agents Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Nuclear Medicine Imaging Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Nuclear Medicine Imaging Agents Revenue Market Share by Application (2021-2032) Figure 29. North America Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Nuclear Medicine Imaging Agents Sales Market Share by Country (2021-2032) Figure 31. U.S. Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Nuclear Medicine Imaging Agents Sales Market Share by Country (2021-2032) Figure 36. Germany Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Nuclear Medicine Imaging Agents Sales Market Share by Country (2021-2032) Figure 43. China Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales Market Share by Country (2021-2032) Figure 51. Brazil Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Nuclear Medicine Imaging Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Nuclear Medicine Imaging Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Nuclear Medicine Imaging Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Nuclear Medicine Imaging Agents Revenue (2021-2032) & (US$ Million) Figure 62. North America Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Nuclear Medicine Imaging Agents Revenue (2021-2032) & (US$ Million) Figure 64. Europe Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Nuclear Medicine Imaging Agents Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Nuclear Medicine Imaging Agents Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Nuclear Medicine Imaging Agents Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Nuclear Medicine Imaging Agents Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Nitrogen 13 Labeling
  • Technetium 99 Labeling
  • Fluorine 18 Labeling
  • Carbon 11 Labeling
  • Oxygen 15 Labeling
  • Others
Applications
  • Clinical Stage
  • Early Diagnosis
  • Treatment Evaluation
Companies covered
  • Jubilant Pharma Limited
  • Foshan Rui Diao Pharmaceutical
  • Yantai Dongcheng
  • Navidea
  • Mallinckrodt
  • Lantheus
  • Guerbet
  • GE HealthCare
  • Eli Lilly and Company
  • Cardinal Health
  • Bracco Diagnostic
  • Blue Earth Diagnostics
  • Bayer AG
  • Abx Advanced Biochemical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nuclear Medicine Imaging Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nuclear Medicine Imaging Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nuclear Medicine Imaging Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nuclear Medicine Imaging Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nuclear Medicine Imaging Agents Market Dynamics
  1. 2.1 Nuclear Medicine Imaging Agents Industry Trends
  2. 2.2 Nuclear Medicine Imaging Agents Industry Drivers
  3. 2.3 Nuclear Medicine Imaging Agents Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Imaging Agents Industry Restraints
3 Nuclear Medicine Imaging Agents Market by Manufacturers
  1. 3.1 Global Nuclear Medicine Imaging Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nuclear Medicine Imaging Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nuclear Medicine Imaging Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nuclear Medicine Imaging Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nuclear Medicine Imaging Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nuclear Medicine Imaging Agents Manufacturers, Product Type & Application
  7. 3.7 Global Nuclear Medicine Imaging Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nuclear Medicine Imaging Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nuclear Medicine Imaging Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nuclear Medicine Imaging Agents Tier 1, Tier 2, and Tier 3
4 Nuclear Medicine Imaging Agents Market by Type
  1. 4.1 Nuclear Medicine Imaging Agents Type Introduction
  2. 4.1.1 Nitrogen 13 Labeling
  3. 4.1.2 Technetium 99 Labeling
  4. 4.1.3 Fluorine 18 Labeling
  5. 4.1.4 Carbon 11 Labeling
  6. 4.1.5 Oxygen 15 Labeling
  7. 4.1.6 Others
  8. 4.2 Global Nuclear Medicine Imaging Agents Sales by Type
  9. 4.2.1 Global Nuclear Medicine Imaging Agents Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Nuclear Medicine Imaging Agents Sales by Type (2021-2032)
  11. 4.2.3 Global Nuclear Medicine Imaging Agents Sales Market Share by Type (2021-2032)
  12. 4.3 Global Nuclear Medicine Imaging Agents Revenue by Type
  13. 4.3.1 Global Nuclear Medicine Imaging Agents Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Nuclear Medicine Imaging Agents Revenue by Type (2021-2032)
  15. 4.3.3 Global Nuclear Medicine Imaging Agents Revenue Market Share by Type (2021-2032)
5 Nuclear Medicine Imaging Agents Market by Application
  1. 5.1 Nuclear Medicine Imaging Agents Application Introduction
  2. 5.1.1 Clinical Stage
  3. 5.1.2 Early Diagnosis
  4. 5.1.3 Treatment Evaluation
  5. 5.2 Global Nuclear Medicine Imaging Agents Sales by Application
  6. 5.2.1 Global Nuclear Medicine Imaging Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nuclear Medicine Imaging Agents Sales by Application (2021-2032)
  8. 5.2.3 Global Nuclear Medicine Imaging Agents Sales Market Share by Application (2021-2032)
  9. 5.3 Global Nuclear Medicine Imaging Agents Revenue by Application
  10. 5.3.1 Global Nuclear Medicine Imaging Agents Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nuclear Medicine Imaging Agents Revenue by Application (2021-2032)
  12. 5.3.3 Global Nuclear Medicine Imaging Agents Revenue Market Share by Application (2021-2032)
6 Global Nuclear Medicine Imaging Agents Sales by Region
  1. 6.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Medicine Imaging Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Nuclear Medicine Imaging Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Nuclear Medicine Imaging Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nuclear Medicine Imaging Agents Revenue by Region
  1. 7.1 Global Nuclear Medicine Imaging Agents Revenue by Region
  2. 7.1.1 Global Nuclear Medicine Imaging Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nuclear Medicine Imaging Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Nuclear Medicine Imaging Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Nuclear Medicine Imaging Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nuclear Medicine Imaging Agents Revenue (2021-2032)
  8. 7.2.2 North America Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nuclear Medicine Imaging Agents Revenue (2021-2032)
  11. 7.3.2 Europe Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nuclear Medicine Imaging Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nuclear Medicine Imaging Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nuclear Medicine Imaging Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Jubilant Pharma Limited
  2. 8.1.1 Jubilant Pharma Limited Company Information
  3. 8.1.2 Jubilant Pharma Limited Business Overview
  4. 8.1.3 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio
  6. 8.1.5 Jubilant Pharma Limited Recent Developments
  7. 8.2 Foshan Rui Diao Pharmaceutical
  8. 8.2.1 Foshan Rui Diao Pharmaceutical Company Information
  9. 8.2.2 Foshan Rui Diao Pharmaceutical Business Overview
  10. 8.2.3 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio
  12. 8.2.5 Foshan Rui Diao Pharmaceutical Recent Developments
  13. 8.3 Yantai Dongcheng
  14. 8.3.1 Yantai Dongcheng Company Information
  15. 8.3.2 Yantai Dongcheng Business Overview
  16. 8.3.3 Yantai Dongcheng Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio
  18. 8.3.5 Yantai Dongcheng Recent Developments
  19. 8.4 Navidea
  20. 8.4.1 Navidea Company Information
  21. 8.4.2 Navidea Business Overview
  22. 8.4.3 Navidea Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Navidea Nuclear Medicine Imaging Agents Product Portfolio
  24. 8.4.5 Navidea Recent Developments
  25. 8.5 Mallinckrodt
  26. 8.5.1 Mallinckrodt Company Information
  27. 8.5.2 Mallinckrodt Business Overview
  28. 8.5.3 Mallinckrodt Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio
  30. 8.5.5 Mallinckrodt Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Nuclear Medicine Imaging Agents Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 Guerbet
  38. 8.7.1 Guerbet Company Information
  39. 8.7.2 Guerbet Business Overview
  40. 8.7.3 Guerbet Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guerbet Nuclear Medicine Imaging Agents Product Portfolio
  42. 8.7.5 Guerbet Recent Developments
  43. 8.8 GE HealthCare
  44. 8.8.1 GE HealthCare Company Information
  45. 8.8.2 GE HealthCare Business Overview
  46. 8.8.3 GE HealthCare Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio
  48. 8.8.5 GE HealthCare Recent Developments
  49. 8.9 Eli Lilly and Company
  50. 8.9.1 Eli Lilly and Company Company Information
  51. 8.9.2 Eli Lilly and Company Business Overview
  52. 8.9.3 Eli Lilly and Company Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio
  54. 8.9.5 Eli Lilly and Company Recent Developments
  55. 8.10 Cardinal Health
  56. 8.10.1 Cardinal Health Company Information
  57. 8.10.2 Cardinal Health Business Overview
  58. 8.10.3 Cardinal Health Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio
  60. 8.10.5 Cardinal Health Recent Developments
  61. 8.11 Bracco Diagnostic
  62. 8.11.1 Bracco Diagnostic Company Information
  63. 8.11.2 Bracco Diagnostic Business Overview
  64. 8.11.3 Bracco Diagnostic Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio
  66. 8.11.5 Bracco Diagnostic Recent Developments
  67. 8.12 Blue Earth Diagnostics
  68. 8.12.1 Blue Earth Diagnostics Company Information
  69. 8.12.2 Blue Earth Diagnostics Business Overview
  70. 8.12.3 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio
  72. 8.12.5 Blue Earth Diagnostics Recent Developments
  73. 8.13 Bayer AG
  74. 8.13.1 Bayer AG Company Information
  75. 8.13.2 Bayer AG Business Overview
  76. 8.13.3 Bayer AG Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayer AG Nuclear Medicine Imaging Agents Product Portfolio
  78. 8.13.5 Bayer AG Recent Developments
  79. 8.14 Abx Advanced Biochemical
  80. 8.14.1 Abx Advanced Biochemical Company Information
  81. 8.14.2 Abx Advanced Biochemical Business Overview
  82. 8.14.3 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio
  84. 8.14.5 Abx Advanced Biochemical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nuclear Medicine Imaging Agents Value Chain Analysis
  2. 9.1.1 Nuclear Medicine Imaging Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nuclear Medicine Imaging Agents Production Mode & Process
  6. 9.2 Nuclear Medicine Imaging Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nuclear Medicine Imaging Agents Distributors
  9. 9.2.3 Nuclear Medicine Imaging Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst